$1.07 +0.03 (%) Prima Biomed Shs Sponsored American Deposit Receipt Repr 30 Shs - NASDAQ

May. 31, 2016 | 02:31 PM

Headlines

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Partner Headlines

  1. Prima BioMed Announces Granting of Patent Number US 9,244,059 Eentitled Cytotoxic Anti-LAG-3 Monoclonal Antibody and its Use in the Treatment or Prevention of Organ Transplant Rejection and Autoimmune Disease'

    Benzinga | Jan. 28, 2016 | 07:15AM EST
  2. US Patent Grants for IMP731 Antibody

    GuruFocus | Jan. 27, 2016 | 23:04PM EST
  3. Prima BioMed Initiates Phase I Melanoma Study in Australia

    GuruFocus | Jan. 26, 2016 | 23:04PM EST
  4. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 31, 2015 | 08:06AM EST
  5. Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer

    GuruFocus | Dec. 22, 2015 | 23:04PM EST
  6. Prima BioMed Initiates Phase IIb Study in Metastatic Breast Cancer

    Benzinga | Dec. 22, 2015 | 07:11AM EST
  7. Prima BioMed Progresses Japanese Collaboration

    GuruFocus | Dec. 11, 2015 | 23:05PM EST
  8. Benzinga's Top #PreMarket Losers

    Benzinga | Dec. 11, 2015 | 08:15AM EST
  9. Benzinga's Top #PreMarket Gainers

    Benzinga | Dec. 11, 2015 | 08:15AM EST
  10. Benzinga's Top Initiations

    Benzinga | Dec. 3, 2015 | 09:47AM EST
  11. Prima BioMed Raises A$2.0 Million Through Placement to Leading Australian Institution

    GuruFocus | Oct. 31, 2015 | 00:02AM EST
  12. Prima BioMed Gains Belgian Regulatory Approval to Commence a Registration Phase IIb Study of IMP321

    GuruFocus | Oct. 28, 2015 | 00:03AM EST
  13. Benzinga's Top Initiations

    Benzinga | Oct. 14, 2015 | 10:13AM EST
  14. Prima BioMed Raises A$1.55M Through Placement to Sophisticated European Healthcare Investor

    GuruFocus | Oct. 14, 2015 | 00:03AM EST
  15. UPDATE: Prima BioMed Raises A$1.55M Through Private Placement to Nyenburgh Investment Partners @A$0.05/Share

    Benzinga | Oct. 13, 2015 | 05:21AM EST
  16. UPDATE: Prima Biomed Receives A$475,000 in Grant Funding from EU, German Free State of Saxony

    Benzinga | Oct. 8, 2015 | 20:36PM EST
  17. Prima Biomed Announces Commencement of Milestones for IMP701 Program

    GuruFocus | Aug. 15, 2015 | 00:06AM EST
  18. Benzinga's Top #PreMarket Gainers

    Benzinga | Aug. 14, 2015 | 08:17AM EST
  19. US Stock Futures Slip Ahead Of Economic Data

    Benzinga | Aug. 14, 2015 | 07:11AM EST
  20. Prima Biomed to Receive Undisclosed Milestone Payment from Novartis

    Benzinga | Aug. 14, 2015 | 04:34AM EST
  21. Prima Biomed Announces Share Purchase Plan

    Benzinga | Jul. 8, 2015 | 06:35AM EST
  22. Benzinga's Top #PreMarket Losers

    Benzinga | Jun. 4, 2015 | 08:28AM EST
  23. Benzinga's Top #PreMarket Gainers

    Benzinga | Jun. 3, 2015 | 08:11AM EST
  24. Benzinga's Top #PreMarket Gainers

    Benzinga | May. 29, 2015 | 08:11AM EST
  25. Benzinga's Top #PreMarket Losers

    Benzinga | May. 28, 2015 | 08:19AM EST
  26. Prima BioMed Receives NASDAQ Notice of Bid Price Deficiency

    GuruFocus | Dec. 29, 2014 | 11:03AM EST
  27. Prima BioMed Announces Immutep's IMP321 Patent Application Receives Canadian Patent Office ...

    GuruFocus | Dec. 22, 2014 | 11:02AM EST
  28. Prima BioMed Completes Immutep Acquisition

    GuruFocus | Dec. 17, 2014 | 11:03AM EST
  29. Prima Biomed Enhances CVac Manufacturing and Logistics Capability

    GuruFocus | Dec. 5, 2014 | 11:02AM EST
  30. CVac Demonstrates Overall Survival Benefit in Second Remission Ovarian Cancer

    GuruFocus | Nov. 6, 2014 | 11:06AM EST
  31. Prima BioMed to Host Conference Call & Webcast to Discuss Acquisition of Immutep

    GuruFocus | Oct. 21, 2014 | 16:04PM EST
  32. Morning Market Movers

    Benzinga | Jul. 16, 2014 | 09:44AM EST
  33. Morning Market Movers

    Benzinga | Nov. 25, 2013 | 10:00AM EST
  34. Stocks Hitting 52-Week Lows

    Benzinga | Sep. 25, 2013 | 10:12AM EST
  35. Stocks Hitting 52-Week Lows

    Benzinga | Sep. 18, 2013 | 10:11AM EST
  36. Morning Market Losers

    Benzinga | Sep. 18, 2013 | 10:06AM EST
  37. Prima BioMed's "CANVAS" Clinical Trial Approved to Start in Korea

    Benzinga | Aug. 14, 2013 | 07:10AM EST
  38. Benzinga's Top Pre-Market Losers

    Benzinga | Aug. 5, 2013 | 08:17AM EST
  39. Morning Market Losers

    Benzinga | Jun. 21, 2012 | 03:49AM EST
  40. From Earlier: Prima BioMed CEO to Step Dowm

    Benzinga | May. 24, 2012 | 01:43AM EST
Trading Center